Toggle light / dark theme

Researchers at Empa and EPFL have created one of the smallest motors ever made. It’s composed of just 16 atoms, and at that tiny size it seems to function right on the boundary between classical physics and the spooky quantum realm.

Like its macroscopic counterparts, this mini motor is made up of a moving part (the rotor) and a fixed part (the stator). The stator in this case is a cluster of six palladium atoms and six gallium atoms arranged in a rough triangular shape. Meanwhile, the rotor is a four-atom acetylene molecule, which rotates on the surface of the stator. The whole machine measures less than a nanometer wide.

The molecular motor can be powered by either thermal or electrical energy, although the latter was found to be much more useful. At room temperature, for example, the rotor was found to rotate back and forth at random. But when an electric current was applied using an electron scanning microscope, the rotor would spin in one direction with a 99-percent stability.

The cocktail, now named REGN-COV2, consists of two antibodies—REGN10933 and REGN10987—that are designed to bind non-competitively to the receptor binding domain of SARS-CoV-2’s spike protein. Regeneron says that such binding diminishes the ability of mutant viruses to escape treatment—with details from preclinical research to be published in upcoming research studies.


Regeneron Pharmaceuticals said today it has launched the first clinical trial of its dual-antibody “cocktail” designed to both prevent and treat COVID-19, as well as prevent viral escape. The cocktail, now named REGN-COV2, consists of two antibodies—REGN10933 and REGN10987—that are designed to bind non-competitively to the receptor binding domain of SARS-CoV-2’s spike protein. [Regeneron].

Chemistry Nobel

Olof Ramström, from the Nobel Committee, said lithium-ion batteries had “enabled the mobile world”.


Three scientists have been awarded the 2019 Nobel Prize in Chemistry for the development of lithium-ion batteries.

John B Goodenough, M Stanley Whittingham and Akira Yoshino share the prize for their work on these rechargeable devices, which are used for portable electronics.

CLEW, an Israeli medtech firm specializing in real-time AI analytics platforms, received approval from the United States Food and Drug Administration (FDA) for its “Predictive Analytics Platform in Support of COVID-19 Patients,” the company announced Tuesday.

The Intensive Care Unit (ICU) solution was given Emergency Use Authorization (EUA) by the FDA so that it may be implemented within the United States’ health system as soon as possible.